Studies related to Plasma Arginine and Arginine

Pharmacokinetic And Pharmacodynamic Properties Of Oral L-citrulline And L-arginine: Impact On Nitric Oxide Metabolism

Effect Increase
Trial Design Double blind
Trial Length 1-7 Days
Number of Subjects 20
Gender Both Genders
Age Range 45-64, 65+
Body Types Overweight, Average
Notes for this study:
Supplemental L-arginine (3g twice a day) was able to increase nitric oxide metabolites without significantly affecting blood flow. ADMA was not increased (the arginine:ADMA ratio actually increased).

Effect Of A Long-term Oral L-arginine Supplementation On Glucose Metabolism: A Randomized, Double-blind, Placebo-controlled Trial

Effect Increase
Trial Design Double blind
Trial Length 6+ Months
Number of Subjects 144
Gender Both Genders
Age Range 45-64, 65+
Body Types Obese
Notes for this study:
In persons with impaired glucose tolerance where 6.4g L-arginine was given daily for 18 months (followed by 12 months of followup), supplementation was associated with improved fat mass and lean mass (increase in lean mass was 0.12+/-1.97, and only statistically significant when compared to the loss seen with placebo) and associated with improved insulin secretion following a test meal. Insulin sensitivity increased by Strumvall but not HOMA-IR, and fasting blood flow and glucose were unaltered.

L-arginine-induced Vasodilation In Healthy Humans: Pharmacokinetic-pharmacodynamic Relationship

Effect Increase
Trial Design Double blind
Trial Length 1-7 Days
Number of Subjects 8
Gender Male
Age Range 18-29
Body Types Average
Notes for this study:
Infusions of arginine were able to reduce blood pressure without affecting heart rate, but 6g oral supplementation failed to replicate these effects.

Effects Of 7 Days Of Arginine-alpha-ketoglutarate Supplementation On Blood Flow, Plasma L-arginine, Nitric Oxide Metabolites, And Asymmetric Dimethyl Arginine After Resistance Exercise

Effect Increase
Trial Design Double blind
Trial Length 1-7 Days
Number of Subjects 24
Gender Male
Age Range 18-29
Body Types Trained, Average
Notes for this study:
7 days supplementation of Arginine AAKG at 12g daily in physically active men failed to influence blood pressure/flow or heart rate and also failed to influence either nitric oxide metabolites or ADMA.

L-arginine Supplementation In Peripheral Arterial Disease: No Benefit And Possible Harm

Effect Increase
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 133
Gender Both Genders
Age Range 65+
Notes for this study:
3g arginine daily for 6 months in persons with peripheral artery disease (intermittent claudication in this study) noted that supplementation was actually adverse to blood flow and symptoms of claudition as assessed by functional testing on a treadmill (reducing a 28.3% improvement to 11.5%).

No Effect Of Short-term Arginine Supplementation On Nitric Oxide Production, Metabolism And Performance In Intermittent Exercise In Athletes

Effect Increase
Trial Design Double blind
Trial Length 1-7 Days
Number of Subjects 10
Gender Male
Age Range 18-29
Body Types Trained, Average
Notes for this study:
Peak and mean power output as well as biomarkers of nitric oxide metabolism (nitrate and nitrite, citrulline) were unaffected in judo athletes given 3 days of 6g L-arginine supplementation prior to a cycle ergometer test. Despite no increase in plasma citrulline, however, an increase in plasma arginine was noted.